Alterity Therapeutics Ltd (ASX: ATH, formerly Prana Biotechnology) is an Australian biotechnology company focused on developing novel disease-modifying therapies for Parkinson's disease and other neurodegenerative disorders characterized by abnormal protein aggregation. The company's lead programs target alpha-synuclein aggregation, the pathological hallmark of Parkinson's disease and related synucleinopathies, through small molecule inhibitors that prevent the formation of toxic protein oligomers and fibrils [1][2][3].
Founded in 1997 as Prana Biotechnology, the company underwent a strategic transformation and rebranded to Alterity Therapeutics in 2021 to reflect its expanded pipeline focus beyond its original mitochondrial targeting programs. The name "Alterity" reflects the company's mission to alter the course of neurodegenerative disease by targeting the fundamental protein aggregation processes that drive neuronal dysfunction and death [1].
Headquartered in Melbourne, Victoria, Australia, Alterity is developing a pipeline of small molecule inhibitors targeting protein aggregation, with lead programs in Parkinson's disease, multiple system atrophy (MSA), and other disorders characterized by alpha-synuclein pathology. The company's approach differs from antibody-based therapies by using brain-penetrant small molecules that can potentially modify disease progression throughout the central nervous system [1][2].
| Attribute | Value |
|---|---|
| Founded | 1997 (as Prana Biotechnology) |
| Headquarters | Melbourne, Victoria, Australia |
| Ticker | ATH (ASX) |
| CEO | Dr. Geoffrey K. H. Loane |
| Market Cap | ~$20M AUD (2025) |
| Employees | ~15-20 |
| Status | Public (ASX listed) |
Prana Biotechnology was founded in 1997 in Melbourne, Australia, with a focus on developing mitochondrial-targeted antioxidants for neurodegenerative diseases. The company's founding science was based on research from the University of Melbourne demonstrating that certain mitochondrial function modulators could protect neurons from oxidative stress and death [1][4].
The company's early development focused on PBT2, a mitochondrial function modulator that showed promise in preclinical models of Alzheimer's disease and Huntington's disease. PBT2 advanced to Phase 2 clinical trials in both indications, demonstrating some evidence of biological activity in cognitive measures [1].
During this period, Prana established collaborations with leading academic institutions including:
In 2021, Prana Biotechnology underwent a significant corporate transformation:
The rebranding recognized that the company's most promising programs centered on protein aggregation inhibition rather than mitochondrial function modulation. This strategic shift aligned with emerging understanding of alpha-synuclein's central role in synucleinopathies and the need for disease-modifying therapies [1][2][3].
Neurodegenerative diseases are characterized by the accumulation of misfolded proteins in the brain. In Parkinson's disease and related disorders, the protein alpha-synuclein forms toxic aggregates that propagate between neurons, leading to progressive dopaminergic neuron loss in the substantia nigra and widespread pathological changes throughout the nervous system [3][5][6].
Alpha-Synuclein Pathophysiology:
Alpha-synuclein is a 140-amino acid protein enriched in presynaptic terminals where it regulates synaptic vesicle trafficking and neurotransmitter release. Under physiological conditions, alpha-synuclein exists in an unfolded state that can adopt alpha-helical structures upon membrane binding. However, in disease states, alpha-synuclein undergoes a conformational transition to beta-sheet rich structures that assemble into toxic oligomers and fibrils [3][5][6].
The aggregation process proceeds through:
Toxicity Mechanisms:
Soluble oligomeric intermediates are now recognized as the most toxic species, causing neuronal dysfunction through multiple mechanisms [3][6][7]:
Alterity's drug discovery platform has identified small molecules that prevent alpha-synuclein aggregation through multiple mechanisms [2][8]:
PBT434 - Lead Program:
PBT434 is a novel quinazolinone-based small molecule that inhibits alpha-synuclein fibril formation and reduces oxidative stress. The compound was optimized through structure-activity relationship studies to achieve:
PBT434 prevents alpha-synuclein misfolding and aggregation by stabilizing the native unfolded state and preventing the conformational transition to beta-sheet structures. This mechanism differs from antibodies that target already-formed aggregates, potentially allowing earlier intervention in disease progression [2][8].
ATH-434 - Second Generation:
ATH-434 is a next-generation aggregation inhibitor with enhanced potency and pharmacokinetic properties. The compound builds on learnings from PBT434 to provide improved brain exposure and target engagement. ATH-434 is in preclinical development for Parkinson's disease and multiple system atrophy [1][2].
ATH-521 - Tau Program:
ATH-521 represents Alterity's expansion into tau protein aggregation inhibition. While alpha-synuclein is the primary target for synucleinopathies, tau pathology co-occurs in many Parkinson's disease patients, particularly those with dementia. ATH-521 aims to provide benefit for patients with mixed pathology [1][2].
| Trial | Phase | Status | Key Findings |
|---|---|---|---|
| Phase 1 | Completed | Safety/tolerability in healthy volunteers | |
| Phase 1b | Completed | PK/PD in Parkinson's disease patients | |
| Preclinical | Ongoing | ATH-434 and ATH-521 development |
Phase 1 Clinical Trial:
PBT434 successfully completed Phase 1 clinical trials demonstrating safety and tolerability in healthy volunteers. The trials established:
Phase 1b in Parkinson's Disease:
A Phase 1b study evaluated PBT434 in patients with early Parkinson's disease, establishing:
ATH-434 is advancing through preclinical development with IND-enabling studies underway. Key differentiators from PBT434 include:
| Drug | Target | Indication | Stage | Status |
|---|---|---|---|---|
| PBT434 | Alpha-synuclein | Parkinson's Disease | Phase 1 | Completed |
| ATH-434 | Alpha-synuclein | Parkinson's Disease/MSA | Preclinical | IND-enabling |
| ATH-521 | Tau protein | Parkinson's Disease Dementia | Preclinical | Research |
Alterity's programs target protein homeostasis networks that become dysregulated in neurodegeneration. The company studies how small molecule inhibitors interact with:
By inhibiting aggregation, the company aims to reduce the burden on these clearance systems, allowing neurons to maintain proteostasis [3][9][10].
The aggregation of alpha-synuclein generates reactive oxygen species through multiple mechanisms:
PBT434 and related compounds reduce oxidative stress through:
Alpha-synuclein oligomers directly impair mitochondrial function by:
Alterity's aggregation inhibitors protect mitochondria by preventing oligomer formation, thereby preserving neuronal energy metabolism and preventing cell death [4][7][8].
Chronic neuroinflammation is a hallmark of Parkinson's disease, with activated microglia surrounding dopaminergic neurons in the substantia nigra. Alpha-synuclein aggregates trigger neuroinflammation through:
By reducing alpha-synuclein aggregation, Alterity's compounds may decrease neuroinflammatory responses and slow disease progression [11].
Alterity occupies a unique position in the Parkinson's disease therapeutic landscape:
Aggregation Inhibitors:
Other PD Approaches:
Advantages of Small Molecule Approach:
Alterity maintains collaborations with leading research institutions:
These collaborations provide access to cutting-edge science and enable clinical development of novel compounds.
As a small biotech company, Alterity's funding comes from:
The company maintains a lean operational structure with 15-20 employees, leveraging CRO partnerships for drug development.
Developing disease-modifying therapies for Parkinson's disease requires careful patient selection to maximize the probability of success:
Biomarker Categories:
Enrichment Strategies:
Alterity is developing biomarker-driven enrichment strategies for clinical trials:
Phase 2 and Phase 3 trials for Parkinson's disease face unique challenges:
Outcome Measures:
Trial Duration:
Regulatory agencies have provided guidance for PD drug development:
Alterity's development strategy includes:
Parkinson's disease represents one of the largest unmet needs in neurology:
Alterity's small molecule approach offers unique commercial advantages:
Competitive Advantages:
Target Patient Populations: